Tech giants are pouring an estimated US$828b into AI infrastructure in 2026, and a chunk of that horsepower is already flowing into healthcare. When that much capital chases one idea, the risk is ignoring where it quietly starts to reshape entire industries. AI in medicine sits at that crossroads, blending software, data and care delivery. This article breaks down three AI focused healthcare stocks from the screener that may be worth putting on your radar.
The three stocks below are just a sample set, and the full screen surfaced 31 more AI focused healthcare companies with equally compelling stories that are not covered here. If you want to identify potential standout ideas early, head straight into the Transformative Artificial intelligence (AI) Healthcare Stocks screener to filter and analyze the wider opportunity set.
GeneDx Holdings (WGS)
GeneDx Holdings uses AI to interpret complex genomic data for rare disease, hereditary risk, and cancer testing. This fits tightly with the screener's focus on diagnostics that rely on machine learning to make healthcare faster, more accurate, and more personalized.
GeneDx Holdings is a genomics testing provider focused on whole exome and genome sequencing, with around US$423 million from segment adjustments and US$31 million from Fabric Genomics and legacy Sema4, and a market value of roughly US$2.1b.
"While management is prioritizing payer coverage and AI driven revenue cycle tools to close the gap between current collection rates around the low 30% range and the longer term ~70% target, the persistence of roughly 32% outpatient genome collections through Q2 2026 suggests that any improvement in net collections and earnings could arrive more slowly than the volume growth in tests."
What happens if a single pressure on GeneDx's AI enabled testing business quietly flips from a headwind to a tailwind for margins?
If that turn in collections is what you are watching, read the full narrative for GeneDx Holdings to see how margin pressure, payer behavior and AI adoption could be decoupling.
Pfizer (PFE)
Pfizer brings the AI healthcare theme into big pharma scale, using biomolecular models and data driven tools inside a broad medicines portfolio to try to make discovery faster and decisions sharper across its global business.
Pfizer develops and sells a wide range of biopharmaceutical treatments, from vaccines and oncology therapies to inflammation and rare disease drugs. It is layering biomolecular AI models from its Boltz collaboration onto this platform. The Global Biopharmaceuticals Business generates about US$62.3b of its revenue, with segment adjustments of roughly US$1.4b, and the group carries a market value near US$170.7b.
"Broader roll out of AI and advanced analytics across R&D, manufacturing and commercial operations, which has already tripled international salesforce productivity and shortened clinical reporting timelines, is designed to keep Pfizer's cost structure efficient and can influence both margins and earnings as these tools are applied more widely."
What happens if that emerging AI engine meets one unresolved pressure on future drug pricing and reimbursement at the same time?
That collision point is exactly where full narrative for Pfizer digs in, mapping how Pfizer's AI push could reshape pricing pressure, productivity and long term earnings power.
HealthStream (HSTM)
HealthStream plugs into the AI healthcare story from a different angle, using software to upgrade how hospitals train and manage clinicians rather than diagnose patients directly.
HealthStream delivers SaaS tools that help US healthcare providers manage learning, credentialing, scheduling and AI driven competency assessments. It generates about US$321 million in Internet Software and Services revenue and carries a market value near US$1 billion.
"Growing use of the hStream platform as an integrated system of record, with customers increasingly signing larger multi year bundles such as Competency Suite and targeted market bundles, can widen HealthStream's revenue base and support steadier adjusted EBITDA margins as more applications connect through shared infrastructure."
What happens if one lingering drag inside HealthStream's older product set eases just as more hospitals lean into that AI centred platform story?
If that shift is what you are betting on, the full narrative for HealthStream explains how HealthStream's AI centred platform, contracts and legacy products could be quietly re-rating the story.
Seeking Alternatives Beyond AI Healthcare?
Fresh ideas move first. By the time momentum is flying, early entry points are already dropping away. Scan these curated picks before the crowd and get in early.
-
Spot cash generative businesses before momentum headlines catch up by running a focused search through the 29 high quality undervalued stocks that filters for quality and balance sheet strength.
-
Chase durable income streams while yields still look appealing by scanning the 5 dividend fortresses built around payout strength and balance sheet resilience.
-
Track real-world automation leaders before robotics and AI adoption stories get fully priced by working through the curated 95 robotics and automation stocks list.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
